EWA
CORT icon

EP Wealth Advisors’s Corcept Therapeutics CORT Stock Holding History

EP Wealth Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$422K Buy
+4,850
New +$293K ﹤0.01% 1107
2025
Q2 		$326K Sell
4,440
-2,410
-35% -$175K ﹤0.01% 970
2025
Q1 		$782K Sell
6,850
-150
-2% -$9.13K 0.01% 561
2024
Q4 		$353K Buy
7,000
+476
+7% +$24.9K ﹤0.01% 808
2024
Q3 		$302K Buy
+6,524
New +$232K ﹤0.01% 859

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EP Wealth Advisors's CORT Position: Q2 2026 in Review

EP Wealth Advisors opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 4,850 shares worth $422K. The stake represents ﹤0.01% of the portfolio and ranks #1107 among its holdings. This is a return to the name: EP Wealth Advisors previously reported a position in CORT as recently as Q2 2025.

EP Wealth Advisors first reported a position in CORT in Q3 2024 and has held it in 5 quarters since. The position peaked at $782K in Q1 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • EP Wealth Advisors held 4,850 shares of Corcept Therapeutics worth $422K as of Q2 2026.
  • Corcept Therapeutics was a new EP Wealth Advisors position in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of EP Wealth Advisors's portfolio in Q2 2026, its #1107 holding.
  • EP Wealth Advisors first reported a position in Corcept Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • EP Wealth Advisors's Corcept Therapeutics position peaked at $782K in Q1 2025.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on EP Wealth Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.